Abstract
BackgroundTeriflunomide and dimethylfumarate are two new oral therapies for relapsing-remitting multiple sclerosis (RRMS). Due to the increase in patients with these treatments, face-to-face interviews were carried out with these patients...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
